ClearPoint Neuro Reports Third Quarter 2024 Results

November 7, 2024 4:05 PM

SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and...

Read more

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

November 7, 2024 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has extended its previously announced Research Funding and Option Agreement (the "Agreement") with The Scripps Research Institute ("TSRI") to advance the development of the Company's program on the combination of systemic...

Read more

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

November 7, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice from The Nasdaq Stock Market ("Nasdaq") as described in a decision dated November 5, 2024, that the Company may continue its listing on...

Read more

Bionoid Pharma, Inc. Engages Olayinka Oyebola & Co. as PCAOB External Auditor for Annual Financial Audit

November 7, 2024 7:30 AM

TORONTO, ON and NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) is pleased to announce the formal engagement of Olayinka Oyebola & Co., a PCAOB-registered firm, as the company's external auditor. This appointment marks an important step in enhancing BINP's commitment to transparency, accountability, and adherence to regulatory standards in financial reporting.Under this agreement, Olayinka Oyebola &...

Read more

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies

November 6, 2024 8:30 AM

POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss...

Read more

Adnexus Biotechnologies Inc. Announces a Merger Agreement to Acquire Sanctum Therapeutics Corporation

November 6, 2024 7:30 AM

DALLAS, TX / ACCESSWIRE / November 6, 2024 / Adnexus Biotechnologies Inc. is pleased to announce the completion of a merger agreement with Sanctum Therapeutics Corporation to acquire Sanctum Therapeutics and its core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise, including technology being developed at the Missouri Innovation Center, Columbia,...

Read more

Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024

November 6, 2024 3:00 AM

LUND, SE / ACCESSWIRE / November 06, 2024 / Alligator Bioscience (STO:ATORX)The data contain efficacy results and correlative outcomes with biomarkers based on a median follow-up of 18 months in OPTIMIZE-1 trialConfirmed ORR of 42.1%, unprecedented median DoR of 12.6 months and a median overall survival of 14.9 months strengthen the earlier reported resultsNear doubling of overall survival estimate at 18 months vis a vis FOLFIRINOXSecond...

Read more

Bionoid Pharma, Inc. Unveils Five-Year Strategic Roadmap

November 5, 2024 7:25 AM

Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) has outlined a five-year roadmap focused on expanding revenue streams and brand presence through a targeted acquisition strategy and a shift toward long-term profitability. Within the first 24 months, BINP plans to acquire revenue-generating websites in the health and wellness sector, with the ultimate goal of achieving a 15% EBITDA margin by year five. Central to this vision is the development and...

Read more

Interim Report July-September 2024

November 5, 2024 2:20 AM

STOCKHOLM, SE / ACCESSWIRE / November 05, 2024 /Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for third quarter 2024."This past quarter was a pivotal period for Vicore, as we continue to make significant strides towards our long-term vision of improving treatment outcomes for patients suffering from...

Read more

Tharimmune Announces Upcoming Conference Presentations

November 4, 2024 9:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.Randy Milby, Chief Executive Officer, will attend the 2024 Spartan Capital Investor Conference being held on November 4, 2024 in New York and hold one-on-one meetings. Interested investors...

Read more

Nitches Inc Launches Groundbreaking Veteran-Led Testing for InTheZone Focused Extreme, With Promising Early Results

November 4, 2024 8:00 AM

Nitches Inc (OTC PINK:NICH) is proud to announce that we have begun our highly anticipated Phase One testing, led by a distinguished U.S. Army veteran, who served as a First Sergeant in Aviation and operated in high-stress roles. This testing is focused on gathering real-world feedback from veterans, law enforcement, and firefighters who operate in intense, high-stakes environments. Due to his notable rank and service, we're withholding his...

Read more

Vicore announces the Nomination Committee for the 2025 Annual General Meeting

November 4, 2024 3:20 AM

STOCKHOLM, SE / ACCESSWIRE / November 04, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, November 4, 2024 - Vicore Pharma Holding AB (publ) (STO:VICO) ("Vicore"), a clinical-stage pharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has appointed the Nomination Committee for the 2025 Annual General Meeting. The three largest shareholders as of August 31, 2024,...

Read more

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

October 31, 2024 4:05 PM

President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence...

Read more

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

October 31, 2024 8:35 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today reported financial results for the third quarter 2024."We are working diligently to collect and analyze the definitive data that we need to complete our PMA application seeking approval from the FDA for the VenoValve and we look forward to releasing that data to the public," commented Robert...

Read more

AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies

October 31, 2024 6:00 AM

AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the expansion of a previous agreement with Gilead Sciences, Inc. (Nasdaq:GILD) to develop novel antibody discovery technologies and discover therapeutic antibodies for Gilead-selected targets.Under the initial agreement in June 2023, AbTherx received worldwide rights to Atlas™ Mice, a suite of...

Read more

Increase in Number of Shares and Votes in Vicore Pharma

October 31, 2024 4:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / October 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, October 31, 2024 - Vicore Pharma Holding AB (publ) (STO: VICO) ("Vicore"), a clinical-stage pharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the number of Vicore shares and votes has increased following (i) the rights issue of shares resolved by the...

Read more

Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB

October 31, 2024 3:40 AM

LUND, SE / ACCESSWIRE / October 31, 2024 / Alligator Bioscience (STO:ATORX) Lund, Sweden, October 31, 2024 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on May 7, 2025, has been appointed.Pursuant to the instruction for the Nomination Committee adopted by the AGM in 2019, the Nomination Committee for the Alligator Bioscience AGM 2025 shall...

Read more

BioInvent International AB: Interim Report January-September 2024

October 31, 2024 3:20 AM

LUND, SWEDEN / ACCESSWIRE / October 31, 2024 / BioInvent International (STO:BINV) "Progress to date brings the company one step closer to addressing the needs for new treatment solutions for patients. As part of our Q3 report, we are today pleased to present continued positive data from the Phase 1 part of the study with BI-1206 as a subcutaneous (SC) formulation for the treatment of NHL. We now have another complete response (CR) and another...

Read more

The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) Selects Indica Labs' HALO AP to Deliver AI-enabled Diagnostics

October 30, 2024 8:00 AM

The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), among the leading institutes for clinical digital pathology and research in the European Union, has partnered with Indica Labs to implement digital primary diagnostics with integrated AI-powered image analysis. IPATIMUP selected the HALO AP® enterprise digital pathology platform from Indica Labs for seamless integration of both off-the-shelf and...

Read more

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

October 30, 2024 8:00 AM

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback from a Scientific Advice meeting with the European Medicines Agency (EMA) that included guidance on a planned Phase 2 trial to advance TH104, the Company's lead clinical-stage candidate for moderate-to-severe pruritus in primary biliary...

Read more